-
-
-
-
-
-
-
bluebird bio (BLUE) Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
-
-
-
-
-
-
-
bluebird bio (BLUE) Announces Proposed $150M Share Offering
-
-
-
-
-
-
-
bluebird bio (BLUE) to Sell Priority Review Voucher, if Granted, for $103M
-
-
-
-
-
-
-
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
-
-
-
-
-
-
-
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusiv
-
-
-
-
-
-
-
bluebird bio (BLUE) Sells Second Priority Review Voucher for $95 Million
-
-
-
-
-
-
-
bluebird bio Sells Priority Review Voucher for $102 Million
-
976,712 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All